Previous 10 | Next 10 |
Taro Pharmaceutical (TARO): Q2 Non-GAAP EPS of $1.09 beats by $0.25; GAAP EPS of -$0.50 misses by $1.34.Revenue of $147.1M (+25.1% Y/Y) beats by $9.87M.Settlements and loss contingencies of $60.0 million reflect an additional legal contingency provision related to ongoing multi-jurisdiction c...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021. The release will be accessible on Taro’s website at www.taro.com . ...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2021, filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor Relations section...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2021. Quarter ended March 31, 2021 Highlights ─ compared to March 31, 2020 Net ...
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2021, on Wednesday, May 19, 2021. The release will be accessible on Taro’s website at www.taro.com . About Taro Taro Pharmaceu...
Taro Pharmaceutical (TARO): Q4 GAAP EPS of $0.86 misses by $0.15.Revenue of $140.1M (-19.9% Y/Y) misses by $12.53M.Press Release For further details see: Taro Pharmaceutical EPS misses by $0.15, misses on revenue
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2020. Quarter ended December 31, 2020 Highlights ─ compared to December 31, 2...
Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP gained 14.7% net in 2020, which compares against the Russell 2000 Index ...
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2020, after the close of market on Wednesday, January 27, 2021. The release will be accessible on Taro’s website a...
Taro Pharmaceutical Industries Ltd. (TARO) Q2 2021 Results Conference Call October 29, 2021 08:00 AM ET Company Participants William Coote - Assistant VP and Treasurer Dilip Shanghvi - Chairman Uday Baldota - CEO Daphne Huang - CFO Conference Call Participants Ram Selvaraju - H.C Wainwright G...
News, Short Squeeze, Breakout and More Instantly...
Taro Pharmaceutical Industries Ltd. Company Name:
TARO Stock Symbol:
NYSE Market:
Taro Pharmaceutical Industries Ltd. Website:
2024-06-03 08:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 09:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Taro Shareholders Approve Merger with Sun Pharma Canada NewsWire MUMBAI, India and NEW YORK , May 23, 2024 /CNW/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiar...